MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
Public ClinicalTrials.gov record NCT02213744. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multicenter, Open Label Study of MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is an open label, randomized, multicenter trial of MM-302 plus trastuzumab. The trial is designed to demonstrate whether MM-302 plus trastuzumab is more effective than the chemotherapy of physician's choice (CPC) plus trastuzumab in locally advanced/metastatic HER2-positive breast cancer patients. Patients may not have been previously treated with an anthracycline in any setting. Patients must have received prior treatment with trastuzumab in any setting, have either progressed or are intolerant to ado-trastuzumab emtansine in the metastatic or locally advanced setting, have either progressed or are intolerant to pertuzumab in the metastatic or locally advanced setting or had disease recurrence within 12 months of pertuzumab treatment in the neoadjuvant or adjuvant setting.
Study identification
- NCT ID
- NCT02213744
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 113 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2014 (Type not available)
- Primary completion
- Dec 2016 (Actual)
- Completion
- Jun 2017 (Estimated)
- Last update posted
- Jan 6, 2017
2014 – 2017
United States locations
- U.S. sites
- 70
- U.S. states
- 28
- U.S. cities
- 61
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Palo Verde Cancer Center | Glendale | Arizona | — | — |
| Mayo Clinic Cancer Center | Scottsdale | Arizona | — | — |
| University of Arizona Cancer Center | Tucson | Arizona | — | — |
| St. Jude Heritage Healthcare | Fullerton | California | — | — |
| UC San Diego Moores Cancer Center | La Jolla | California | — | — |
| Ronald Reagan UCLA Medical Center | Los Angeles | California | — | — |
| Cancer Care Associates Medical Group | Redondo Beach | California | — | — |
| UCSF Medical Center | San Francisco | California | — | — |
| Sansum Clinic | Santa Barbara | California | — | — |
| Kaiser Permanent Medical Center | Vallejo | California | — | — |
| University of Colorado Cancer Center | Aurora | Colorado | — | — |
| Rocky Mountain Cancer Centers | Littleton | Colorado | — | — |
| Smilow Cancer Hospital at Yale New Haven Hospital | New Haven | Connecticut | — | — |
| Washington Cancer Institute | Washington D.C. | District of Columbia | — | — |
| Florida Cancer Specialists & Research Institute | Fort Meyers | Florida | — | — |
| Memorial Regional Hospital | Hollywood | Florida | — | — |
| Mayo Clinic Cancer Center | Jacksonville | Florida | — | — |
| Sarah Cannon Research Institute | New Port Richey | Florida | — | — |
| UF Health Cancer Center at Orlando Health | Orlando | Florida | — | — |
| Florida Cancer Research Institute | Plantation | Florida | — | — |
| University of Miami Comprehensive Cancer Center | Plantation | Florida | — | — |
| Southeastern Regional Medical Center | Newnan | Georgia | — | — |
| Northwestern University- Robert H. Lurie Comprehensive Cancer Center | Chicago | Illinois | — | — |
| Rush University Medical Center | Chicago | Illinois | — | — |
| University of Chicago | Chicago | Illinois | — | — |
| Joliet Oncology-Hematology Associates | Joliet | Illinois | — | — |
| Midwestern Regional Medical Center | Zion | Illinois | — | — |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | — | — |
| McFarland Clinic PC | Ames | Iowa | — | — |
| Johns Hopkins Medicine- The Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | — | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | — | — |
| St. Joseph Mercy Hospital | Ann Arbor | Michigan | — | — |
| University of Michigan Health System | Ann Arbor | Michigan | — | — |
| Minnesota Oncology Hematology | Coon Rapids | Minnesota | — | — |
| University of Minnesota- Masonic Cancer Center | Minneapolis | Minnesota | — | — |
| Mayo Clinic Cancer Center | Rochester | Minnesota | — | — |
| Saint Luke's Hospital | Kansas City | Missouri | — | — |
| Barnes-Jewish West County Hospital | St Louis | Missouri | — | — |
| Hackensack University Medical Center | Hackensack | New Jersey | — | — |
| New Mexico Cancer Care Alliance | Albuquerque | New Mexico | — | — |
| New York Oncology Hematology, P.C. | Albany | New York | — | — |
| North Shore Hematology Oncology Associates | East Setauket | New York | — | — |
| Morton Coleman MD | New York | New York | — | — |
| NYU Langone Medical Center | New York | New York | — | — |
| Montefiore Medical Center | The Bronx | New York | — | — |
| Office of Carey K. Anders | Chapel Hill | North Carolina | — | — |
| Duke Cancer Institute | Durham | North Carolina | — | — |
| Oncology Hematology Care | Cincinnati | Ohio | — | — |
| Cleveland Clinic | Cleveland | Ohio | — | — |
| Ohio State University Hospital | Columbus | Ohio | — | — |
| St. Charles Health System | Bend | Oregon | — | — |
| Magee-Womens Hospital of UPMC | Pittsburgh | Pennsylvania | — | — |
| Bon Secours Saint Francis Hospital Cancer Center | Greenville | South Carolina | — | — |
| Greenville Health System Cancer Institute | Greenville | South Carolina | — | — |
| Tennessee Oncology | Chattanooga | Tennessee | — | — |
| The Sarah Cannon Research Institute | Nashville | Tennessee | — | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | — | — |
| Texas Oncology- Central Austin Cancer Center | Austin | Texas | — | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | — | — |
| Texas Oncology- Medical City | Dallas | Texas | — | — |
| Texas Oncology | El Paso | Texas | — | — |
| The Center for Cancer and Blood Disorders | Fort Worth | Texas | — | — |
| Texas Oncology-Houston Memorial City | Houston | Texas | — | — |
| The University of Texas- MD Anderson Cancer Center | Houston | Texas | — | — |
| Cancer Care Centers of South Texas | San Antonio | Texas | — | — |
| Texas Oncology | Tyler | Texas | — | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | — | — |
| Virginia Oncology Associate | Norfolk | Virginia | — | — |
| Swedish Medical Center | Issaquah | Washington | — | — |
| Northwest Medical Specialties | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02213744, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 6, 2017 · Synced Nov 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02213744 live on ClinicalTrials.gov.